Erratum: Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer (Scientific Reports (2016) 6 (20090) DOI: 10.1038/srep20090);Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Sheng, Jin ^a   Fang, Wenfeng ^a   Yu, Juan ^a   Chen, Nan ^b   Zhan, Jianhua ^a   Ma, Yuxiang ^a   Yang, Yunpeng ^a   Yanhuang, ^a   Zhao, Hongyun ^a   Zhang, Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADULT; AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD274; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 84956607290     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23850     Document Type: Erratum

References (38)

1. Parkin, D. M., Bray, F., Ferlay, J., Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2), 74 (2005).
2. Jemal, A., Siegel, R., Xu, J., Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60 (5), 277 (2010).
3. Sun, S., Schiller, J. H., Spinola, M., Minna, J. D. New molecularly targeted therapies for lung cancer. J Clin Invest 117 (10), 2740 (2007).
4. McDermott, D. F., Atkins, M. B. PD-1 as a potential target in cancer therapy. Cancer Med 2 (5), 662 (2013).
5. Keir, M. E., Butte, M. J., Freeman, G. J., Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 677 (2008).
6. Dong, H., Zhu, G., Tamada, K., Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 5 (12), 1365 (1999).
7. Butte, M. J. et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27 (1), 111 (2007).
8. Park, J. J. et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116 (8), 1291 (2010).
9. Yang, J. et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 187 (3), 1113 (2011).
10. Topalian, S. L., Drake, C. G., Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 24 (2), 207 (2012).
11. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 (19), 3167 (2010).
12. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (7528), 563 (2014).
13. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (26), 2455 (2012).
14. Brahmer, J. R., Hammers, H., Lipson, E. J. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol 11 (9), 1307 (2015).
15. Ghebeh, H. et al. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 8 (3), 190 (2006).
16. Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104 (9), 3360 (2007).
17. Thompson, R. H. et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66 (7), 3381 (2006).
18. Liang, M., Yang, H., Fu, J. Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett 276 (1), 47 (2009).
19. Azuma, K. et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol 25 (10), 1935 (2014).
20. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 4 (127) 127r (2012).
21. Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13 (1), 84 (2007).
22. Zhang, P., Su, D. M., Liang, M., Fu, J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 45 (5), 1470 (2008).
23. Ghebeh, H. et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res 12 (4), R48 (2010).
24. Zitvogel, L., Apetoh, L., Ghiringhelli, F., Kroemer, G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 (1), 59 (2008).
25. Correale, P. et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23 (35), 8950 (2005).
26. Galluzzi, L., Senovilla, L., Zitvogel, L., Kroemer, G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11 (3), 215 (2012).
27. Patel, S. P., Kurzrock, R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther 14 (4), 847 (2015).
28. Kerr, K. M. et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? J Thorac Oncol 10 (7), 985 (2015).
29. Gao, Q. et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15 (3), 971 (2009).
30. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (4), 252 (2012).
31. Chen, N. et al. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. J Thorac Oncol 10 (6), 910 (2015).
32. Afreen, S., Dermime, S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol Oncol Stem Cell Ther 7 (1), 1 (2014).
33. Yang, C. Y. et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. Eur J Cancer 50 (7), 1361 (2014).
34. Konishi, J. et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 10 (15), 5094 (2004).
35. Mu, C. Y. et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 28 (3), 682 (2011).
36. Cooper, W. A. et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer-J Iaslc 89 (2), 181 (2015).
37. Antonia, S. J. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (Pt-DC) in advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 32, 8113 (2014).
38. Tang, Y. et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 6 (16), 14209 (2015).